A randomized, double blind, parallel-group, placebo controlled study to evaluate the efficacy and safety of IBP-9414 in premature infants 500-1500g birth weight in the prevention of necrotizing enterocolitis - The Connection Study

About this Study

To evaluate the efficacy of IBP-9414 vs. placebo on the prevention of necrotizing enterocolitis and on sustained feeding tolerance in very low birth weight premature infants, as well as the safety of IBP-9414 vs. placebo. The study is powered on the necrotizing enterocolitis endpoint. 

Sponsor Protocol ID:IBP-9414-020
IRB Number:2019-0139
Actively Enrolling
Interventional
Phase 3
June 24, 2019
Eligibility Criteria
Both Male and Female
No
Yes
No

Inclusion Criteria1. Gestational age at birth of 23 weeks + 0 days -32 weeks + 0 days

 2. Birth weight 500-1500g. (First infants with birth weights 750-1000g will be included. After a DMC recommendation, infants with birth weights 500-1000g will then be included. After 1400 subjects in the study, infants with birth weights 500-1500g will then be included.)

 3. ≤ 48 hours of age 

4. Written informed consent from the subject´s legally authorized representative (LAR)

Exclusion Criteria1. Participation in any other interventional clinical trial 

2. Infants in extremis to whom no further intensive care is offered by attending neonatologist (e.g., infant being provided only hospice/comfort care) 

3. Infants with, or at a high probability for, early onset sepsis 

4. Infants with recognized chromosomal anomalies 

5. Congenital or acquired gastrointestinal disease 

6. Earlier or planned administration of formulas, foods or supplements that contain added live bacteria, including all infant formulas or food supplement products with added so-called ”probiotic” or added live bacterial content during the study 

7. Infants with known positive maternal HIV status 

Categories Click category to view its trials.
Pediatrics
Participating Locations
Children’s of Mississippi Hospital - Blair E. Batson Tower
Wiser Hospital for Women and Infants - UMMC
Contact Information
Contact Name: Sandra Tyler
Phone Number: 601-815-9479
Email: sltyler@umc.edu
Principal Investigator:Famuyide, Mobolaji E, M.D., M.P.H., M.A.
How to participate in our Clinical Trials